GlobeNewswire

Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors

Del

WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of Jeryl Hilleman to the Board of Directors of the Company. 

"Jeri brings a broad life sciences background to Minerva that includes high growth commercial biopharma, med-tech and data science companies," said William F. Doyle, Lead Independent Director of Minerva.  "Her track record of delivering strategic and financial growth through execution, strategic partnering and multiple acquisitions will serve Minerva well as the Company completes five ongoing late-stage clinical trials with roluperidone, seltorexant and MIN-117."

Ms. Hilleman is presently Chief Financial Officer of Intersect ENT (NASDAQ:XENT), a medical device company with commercial products for the treatment of chronic sinusitis.  Previously, she served as CFO of several public companies, including Amyris, a renewable products company, Symyx Technologies (acquired), which provided research services, software and instrumentation, Ocera (acquired), a biopharma company, and Cytel (acquired), an immunotherapy company. Ms. Hilleman served as a member of the Board of Directors and Chair of the Audit Committee of Xenoport, Inc. (acquired), a commercial biopharma company, for over ten years, from IPO through acquisition. Ms. Hilleman holds an A.B. from Brown University and an M.B.A. from the Wharton Graduate School of Business. She is a member of the 1999 class of Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute.

About Minerva Neurosciences:

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases.  Minerva's proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson's disease.  Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV."  For more information, please visit www.minervaneurosciences.com.

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to Ms. Hilleman's positive impact on us, including as we proceed through clinical trials.  These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, Ms. Hilleman's and our ability to perform as expected.  These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed with the Securities and Exchange Commission on May 3, 2018.  Copies of reports filed with the SEC are posted on our website at  www.minervaneurosciences.com . The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

Contact :

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Tenaris Convenes General Meeting of Shareholders27.6.2019 00:04:00 CESTPressemelding

LUXEMBOURG, June 26, 2019 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE, Buenos Aires and Mexico: TS and MTA Italy: TEN) announces that it has published the convening notice to the General Meeting of Shareholders that will be held on July 29, 2019, at 11:00 a.m. (Central European Time) at Tenaris’s registered office, located at 29, avenue de la Porte-Neuve, 3rd Floor, L-2227 Luxembourg, to consider, and if thought fit, approve the delisting of Tenaris’s shares from the Buenos Aires stock exchange, Bolsas y Mercados Argentinos S.A., through a voluntary withdrawal from listing. The convening notice (which includes the agenda for the meeting and the procedures for attending and/or voting at the meeting) can be downloaded from the Luxembourg Stock Exchange’s website at www.bourse.lu/regulated-information-oam. In addition, the convening notice, together with the total number of shares and voting rights as of the date of the convening notice, and the proxy materials for the meeting (which include t

Acreage Obtains Final Order for Plan of Arrangement with Canopy Growth and Confirms Record Date for Acreage Shareholders Entitled to Receive the Option Premium26.6.2019 23:20:00 CESTPressemelding

NEW YORK, June 26, 2019 (GLOBE NEWSWIRE) -- On June 21, 2019, Acreage Holdings, Inc. (“Acreage”) (CSE:ACRG.U) (OTC: ACRGF) (FSE: 0ZV) obtained a final order from the Supreme Court of British Columbia approving the previously announced arrangement under section 288 of the Business Corporations Act (British Columbia) with Canopy Growth Corporation (“Canopy Growth”) (TSX:WEED) (NYSE:CGC) (together with Acreage, the “Companies”) (the “Arrangement”). On June 19, 2019, each of Acreage and Canopy Growth received all necessary shareholder approvals in connection with the Arrangement at their respective special shareholder meetings. Pursuant to the Arrangement, Canopy Growth will be provided with the option (the “Canopy Growth Call Option”) to acquire all of the issued and outstanding shares in the capital of Acreage (each, an “Acreage Share”), with a requirement to do so upon a change in federal laws in the United States to permit the general cultivation, distribution and possession of marijua

ERYTECH Announces Enrollment of First Patient in Phase 2 Clinical Trial Evaluating Eryaspase in TNBC26.6.2019 23:00:00 CESTPressemelding

LYON, France and CAMBRIDGE, Mass., June 26, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first patient has been enrolled in its Phase 2 clinical trial, named TRYbeCA2, evaluating its lead product candidate eryaspase for the treatment of first line triple negative breast cancer (TNBC). Following the positive Phase 2 results with eryaspase in second-line metastatic pancreatic cancer, ERYTECH selected triple-negative breast cancer as the next indication to expand the potential use of eryaspase in solid tumors. TNBC is an aggressive and metabolically active form of breast cancer with high rates of symptomatic metastases. A Phase 2/3 clinical trial in first-line metastatic TNBC, named TRYbeCA2, was designed and the Phase 2 part of the trial was launched in Spain, Belgium, Hungary and the United Kingdom. The t

EXIDE TECHNOLOGIES COMPLETES COMPREHENSIVE NEW FINANCING AND RECAPITALIZATION26.6.2019 19:37:00 CESTPressemelding

Milton, GA, June 26, 2019 (GLOBE NEWSWIRE) -- Exide Technologies (or the “Company”) (www.exide.com), a global leader in stored energy solutions for the automotive and industrial markets, today announced the completion of a comprehensive new financing and recapitalization transaction led by the Company’s institutional shareholders which has enhanced the Company’s liquidity, extended debt maturities and deleveraged its balance sheet. Issued $150 million new international notes, net proceeds of approximately $125 million Converted $175 million of existing second lien notes to equity Extended first lien note maturity to 2024 from 2022 in an exchange offer Extended second lien note maturity to 2027 from 2025 in an exchange offer Extended ABL credit facility maturity to July 2021 from January 2020 “We believe this transaction is a great outcome for Exide and is intended to significantly improve Exide’s financial position allowing for further growth and continued reinvestment in our business,

FIDO Alliance Announces New Identity Verification and IoT Initiatives to Expand the Reach and Impact of FIDO Authentication26.6.2019 16:30:00 CESTPressemelding

New working groups formed to secure adjacent technologies that are critical for end-to-end identity lifecycle management WASHINGTON, June 26, 2019 (GLOBE NEWSWIRE) -- IDENTIVERSE -- The FIDO Alliance today announced two new standards and certification initiatives in identity verification and the Internet of Things (IoT). These initiatives build upon the Alliance’s ongoing focus on driving the efficacy and market adoption of FIDO Authentication by addressing adjacent technology areas that leave security vulnerabilities on the web. Specifically, the Alliance aims to strengthen identity verification assurance to support better account recovery, and automate secure device onboarding to remove password use from IoT. The Alliance has formed two new working groups: the Identity Verification and Binding Working Group (IDWG) and the IoT Technical Working Group (IoT TWG) to establish guidelines and certification criteria in these areas. The FIDO Alliance will continue to focus on development and

Enablon’s Sustainable Performance Forum (SPF) Focuses on the Future of EHS, Risk and Sustainability26.6.2019 16:21:00 CESTPressemelding

New Risk, Safety and Sustainability innovations in mobility, IOT integrations, and artificial intelligence (AI) used live on stage with early-adopter customers CHICAGO and PARIS, June 26, 2019 (GLOBE NEWSWIRE) -- Wolters Kluwer’s Enablon, a global leader in EHS, Risk and Sustainability Management software, announced at SPF 2019 new innovations executing on its Industry 4.0 Connected Enterprise strategy. The global SPF conference series leads the industry with more than 1,000 attendees from over 35 countries, 20 industry user groups, 120 expert sessions and 80 customer and partner presentations. At SPF Americas and SPF EMEA, Enablon announced new solutions across its suite of applications in Health & Safety Management, Governance, Risk & Compliance, Environmental Management & Sustainability, Process Safety & Control of Work, and Product Stewardship & Quality. The conferences focused on execution against Enablon’s Industry 4.0 Connected Enterprise vision, announcing new platform innovati